MetPath Review Center

Enriching the minds of laboratory scientists worldwide


Mondays - Thursdays
9:00 AM - 4:00 PM
1st batch: MAR 6, 2017
2nd batch: APR 17, 2017
3rd batch: MAY 2, 2017
4th batch: MAY 15, 2017
5th batch: JUN 5, 2017
6th batch: JUL 3, 2017

Each batch will take two (2) intensive review months.
Applicable for In-House and Online Review.
Registration starts on March 1, 2016.
For reservations, kindly complete the RESERVATION FORM online.

For ASCP/AMT/HA-AD/CSMLS/AIMS Review, interested individual can start anytime once enrolled.

  • MetPath Weekly Review Schedules 

    Weekly Review Schedules
    Weekday (Monday - Thursday) 9:00AM - 12:00PM/1:00PM- 4:00PM
    Weekend (Saturday)
    9:00AM - 12:00PM/1:00PM - 4:00PM

    • A registrant may choose to join in any or all of the above review schedules.
    • Applicable to both In-house and Online review.
    • For ASCP/AMT/HA-AD/CSMLS/AIMS Review, interested individual can enroll and start anytime.
    • Time schedules are based on PHIL timezone.

    Online Review Time Schedules (Worldwide)

     Sydney, Australia
    11:00 AM - 7:00 PM

    9:00 AM - 5:00 PM

    Toronto, Canada
    8:30 PM (starting time)  

    New Delhi, India
    8:00 AM - 2:30 PM 

    Jakarta, Indonesia
    8:00 AM - 4:00 PM

    Tokyo, Japan
    10:00 AM - 6:00 PM

    7:00 AM - 2:30 PM (FRIDAYS)

    8:00 AM - 3:30 PM (FRIDAYS)

    USA (starting time of class)
    Hawaii 2:00 PM
    Alaska 4:00 PM

    California 5:00 PM
    Illinois 7:00 PM
    New York 8:00 PM





    Congratulations! (JAN 2018)

    Eanne Jairah Reyes, MLS(ASCP)
    Stella Ramirez, MLS(ASCP)
    Lee Marco Mutia, MLS(ASCP)
    Mary Clare Cesar, MLS(ASCP)
    Mariam Louise Nisal, MLS(ASCP)

    Main Center

    104 Jaltan Bldg.
    CM Recto cor Bonifacio Street,
    Davao City 8000, PHL         

    DTI Cert. No. 00147471

    Share MetPath to a friend

    Recent Diagnostic Posts

    Safety Tests Of Ebola Vaccines To Start This Fall.


    The AP (8/15, Perrone, Neergaard) reports that safety trials are to begin for two experimental Ebola vaccines. Safety tests “typically are performed on a few dozen to 100 people.” The first, “developed by researchers at the National Institutes of Health” and GlaxoSmithKline should be tested in the next few months and is “based on a chimpanzee adenovirus.” Dr. Anthony Fauci has explained that it is “purely preventive, more aimed at giving it to the health care workers who put themselves at considerable danger.” The second, developed by researchers at the Canadian national laboratory and NewLink Genetics of Ames, Iowa, is expected to be tested “in up to 100 health volunteers with the FDA” though the timetable has not been set. The NIH is also supporting development of “at least two other candidate Ebola vaccines,” the first from Crucell, which “could begin human testing by late 2015,” and the second from Profectus Biosciences.